Skip NavigationSkip to Content

Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function

  1. Author:
    Richards, S. M.
    Murphy, W. J.
  2. Author Address

    Genzyme Corp, Dept Cell & Prot Therapeut, Boston, MA USA. Genzyme Corp, Dept Cell & Prot Therapeut, Boston, MA USA. NCI, Frederick Canc Res & Dev Ctr, IRSP, SAIC Frederick, Frederick, MD USA.
    1. Year: 2000
  1. Journal: Journal of Neuroimmunology
    1. 109
    2. 1
    3. Pages: 56-62
  2. Type of Article: Article
  1. Abstract:

    The conclusion that prolactin plays a role in immune and hematopoietic function was initially based upon observations in hormone deficient animals. The multiple cell function defects associated with hypophysectomy or bromocriptine treatment were reversed by administration of prolactin. Since these initial observations, an increasing body of literature supports prolactin having a role in the immune and hematopoietic system. A recombinant form of human prolactin (r-hPRL) has been produced and evaluated in a wide variety of preclinical models. Both in vitro and in vivo studies suggest that r-hPRL can enhance cell function, accelerate lymphoid and myeloid reconstitution and promote hematopoiesis. The multi-lineage effect of r-hPRL makes it an attractive candidate for clinical situations presenting with immune deficiency or myelosuppression. (C) 2000 Published by Elsevier Science B.V.

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel